Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 18/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.61 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913984 | 1.00 | ABCB1 (0.61) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL1667395 | 0.81 | ABCB1 (0.74) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL11918299 | 0.80 | ABCB1 (0.77) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL1667386 | 0.79 | ABCB1 (0.59) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL16730120 | 0.76 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41413 | 0.76 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL27865 | 0.76 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL30416841 | 0.76 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL11913983 | 0.76 | ABCB1 (0.48) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41412 | 0.76 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ABCB1 75/4885LMNA 4530/4885CYP1A2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.